Arthneeti
AH

Amrutanjan Health Care Ltd

Q3 FY24Pharmaceuticals & Biotechnology

Amrutanjan Health Care Ltd Q3 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book

Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹510
Market cap₹1.4K Cr
P/E23.0
Updated24 Sept 2026
Read3 min read

Based on Amrutanjan Health Care Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3 FY24 net sales: - OTC: Rs. The presentation does not explicitly provide EBITDA or operating margin figures for the quarter ended December 31, 2023. - Profit After Tax (PAT) for Q3 FY24 is Rs.

From Amrutanjan Health Care Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY24 net sales:
  • OTC: Rs. 111.79 Cr (up 19.55% YoY)
  • Beverages: Rs. 5.18 Cr (up 41.92% YoY)
  • Comfy: Rs. 30.18 Cr (up 67.11% YoY)
  • Electro Plus: Rs. 4.86 Cr (up 59.87% YoY)
  • Total Net Sales: Rs. 116.99 Cr (up 19.81% YoY)
  • Q3 FY24 profit:
  • Profit Before Tax: Rs. 23.71 Cr (up 63.52%)
  • Profit After Tax: Rs. 17.45 Cr (up 62.93%)
  • Volume outlook:
  • Balm SKU 8ml grew double digits in Q3; cautiously optimistic about sustaining growth.
  • Comfy sales grew 67.11% in Q3; projected to cross Rs. 100 Cr (INR 1 Billion) revenue annually.
  • Growth expected in large packs of Comfy pads as consumers trade up.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly mention any details about capex, capacity expansion, new plants, or projects with amounts, status, or timelines. The slides focus on financial performance, segment growth, operational updates (like IT projects and sales/distribution improvements), and marketing activities but do not provide information on capital expenditures or capacity expansion initiatives.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for the quarter ended 31st December 2023 does not report or mention any information regarding order books, order inflows, or pending orders. - There are no references to order book status or order inflow figures. - No data or commentary is provided on pending orders. - The presentation focuses primarily on sales performance, financial results, operational updates, marketing activities, and management commentary. All quantitative disclosures relate to net sales, revenues, expenses, profits, stock levels, and sales growth across product segments, with no details on orders or order backlog.

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Amrutanjan Health Care Ltd's management said in earlier quarters

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q3 FY24 results?

Q3 FY24 net sales: - OTC: Rs. The presentation does not explicitly provide EBITDA or operating margin figures for the quarter ended December 31, 2023. - Profit After Tax (PAT) for Q3 FY24 is Rs.

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amrutanjan Health Care Ltd planning capital expenditure?

The investor presentation does not explicitly mention any details about capex, capacity expansion, new plants, or projects with amounts, status, or timelines.

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.